Аннотация:Immune checkpoint inhibitors have been a breakthrough in the treatment of many types of cancer, but at the same time this group of drugs is associated with a wide range of adverse effects. Dermatological adverse events are no exception and are very often the first to develop. Furthermore, skin toxicity significantly reduces cancer patients’ quality of life and often leads to discontinuation of therapy. Understanding the structure of immune checkpoint inhibitors’ dermatological adverse events will increase the efficacy of diagnosing these side effects, which will contribute to timely prescription of dermatologic supportive therapy.The aim of this study was to characterize the pattern of skin toxicity in patients undergoing cancer immunotherapy
